vs
GETTY REALTY CORP（GTY）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
MESA LABORATORIES INC的季度营收约是GETTY REALTY CORP的1.1倍（$65.1M vs $57.8M），GETTY REALTY CORP净利率更高（46.0% vs 5.6%，领先40.5%），GETTY REALTY CORP同比增速更快（10.5% vs 3.6%），过去两年GETTY REALTY CORP的营收复合增速更高（7.6% vs 5.1%）
Getty Realty Corp是一家总部位于美国的上市房地产投资信托（REIT），主要持有、租赁并管理商业地产资产组合，核心资产涵盖便利店、加油站及配套零售物业，业务覆盖美国多个州，服务零售与能源领域的优质租户。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
GTY vs MLAB — 直观对比
营收规模更大
MLAB
是对方的1.1倍
$57.8M
营收增速更快
GTY
高出6.9%
3.6%
净利率更高
GTY
高出40.5%
5.6%
两年增速更快
GTY
近两年复合增速
5.1%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $57.8M | $65.1M |
| 净利润 | $26.6M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | 66.1% | 12.2% |
| 净利率 | 46.0% | 5.6% |
| 营收同比 | 10.5% | 3.6% |
| 净利润同比 | 80.1% | 316.6% |
| 每股收益（稀释后） | $0.43 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GTYMLAB
| Q1 26 | $57.8M | — | ||
| Q4 25 | $60.5M | $65.1M | ||
| Q3 25 | $55.6M | $60.7M | ||
| Q2 25 | $53.3M | $59.5M | ||
| Q1 25 | $52.3M | $62.1M | ||
| Q4 24 | $53.0M | $62.8M | ||
| Q3 24 | $51.5M | $57.8M | ||
| Q2 24 | $49.9M | $58.2M |
净利润GTYMLAB
| Q1 26 | $26.6M | — | ||
| Q4 25 | $27.0M | $3.6M | ||
| Q3 25 | $23.3M | $2.5M | ||
| Q2 25 | $14.0M | $4.7M | ||
| Q1 25 | $14.8M | $-7.1M | ||
| Q4 24 | $22.3M | $-1.7M | ||
| Q3 24 | $15.3M | $3.4M | ||
| Q2 24 | $16.7M | $3.4M |
毛利率GTYMLAB
| Q1 26 | — | — | ||
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% |
营业利润率GTYMLAB
| Q1 26 | 66.1% | — | ||
| Q4 25 | 67.3% | 12.2% | ||
| Q3 25 | 62.5% | 7.8% | ||
| Q2 25 | 46.7% | 5.1% | ||
| Q1 25 | 50.5% | 2.4% | ||
| Q4 24 | 61.6% | 9.2% | ||
| Q3 24 | 48.9% | 6.1% | ||
| Q2 24 | 52.5% | 9.6% |
净利率GTYMLAB
| Q1 26 | 46.0% | — | ||
| Q4 25 | 44.7% | 5.6% | ||
| Q3 25 | 42.0% | 4.1% | ||
| Q2 25 | 26.3% | 8.0% | ||
| Q1 25 | 28.3% | -11.4% | ||
| Q4 24 | 42.1% | -2.7% | ||
| Q3 24 | 29.8% | 5.9% | ||
| Q2 24 | 33.5% | 5.8% |
每股收益（稀释后）GTYMLAB
| Q1 26 | $0.43 | — | ||
| Q4 25 | $0.46 | $0.65 | ||
| Q3 25 | $0.40 | $0.45 | ||
| Q2 25 | $0.24 | $0.85 | ||
| Q1 25 | $0.25 | $-1.30 | ||
| Q4 24 | $0.38 | $-0.31 | ||
| Q3 24 | $0.27 | $0.63 | ||
| Q2 24 | $0.30 | $0.62 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.7M | $29.0M |
| 总债务越低越好 | — | $68.4M |
| 股东权益账面价值 | — | $186.7M |
| 总资产 | $2.2B | $434.8M |
| 负债/权益比越低杠杆越低 | — | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资GTYMLAB
| Q1 26 | $3.7M | — | ||
| Q4 25 | $8.4M | $29.0M | ||
| Q3 25 | $5.2M | $20.4M | ||
| Q2 25 | $7.5M | $21.3M | ||
| Q1 25 | $6.3M | $27.3M | ||
| Q4 24 | $9.5M | $27.3M | ||
| Q3 24 | $4.0M | $24.3M | ||
| Q2 24 | $4.7M | $28.5M |
总债务GTYMLAB
| Q1 26 | — | — | ||
| Q4 25 | $995.0M | $68.4M | ||
| Q3 25 | $934.6M | $69.4M | ||
| Q2 25 | $919.2M | $70.3M | ||
| Q1 25 | $901.4M | $71.3M | ||
| Q4 24 | $904.3M | $72.2M | ||
| Q3 24 | $833.9M | $73.1M | ||
| Q2 24 | $838.4M | $74.1M |
股东权益GTYMLAB
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $186.7M | ||
| Q3 25 | $1.0B | $178.5M | ||
| Q2 25 | $982.4M | $172.5M | ||
| Q1 25 | $961.1M | $159.8M | ||
| Q4 24 | $962.1M | $155.2M | ||
| Q3 24 | $963.4M | $161.5M | ||
| Q2 24 | $951.0M | $150.7M |
总资产GTYMLAB
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $434.8M | ||
| Q3 25 | $2.1B | $430.4M | ||
| Q2 25 | $2.0B | $435.7M | ||
| Q1 25 | $2.0B | $433.3M | ||
| Q4 24 | $2.0B | $433.3M | ||
| Q3 24 | $1.9B | $454.1M | ||
| Q2 24 | $1.9B | $440.4M |
负债/权益比GTYMLAB
| Q1 26 | — | — | ||
| Q4 25 | 0.93× | 0.37× | ||
| Q3 25 | 0.92× | 0.39× | ||
| Q2 25 | 0.94× | 0.41× | ||
| Q1 25 | 0.94× | 0.45× | ||
| Q4 24 | 0.94× | 0.47× | ||
| Q3 24 | 0.87× | 0.45× | ||
| Q2 24 | 0.88× | 0.49× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流GTYMLAB
| Q1 26 | — | — | ||
| Q4 25 | $127.4M | $18.8M | ||
| Q3 25 | $30.5M | $8.2M | ||
| Q2 25 | $34.7M | $1.9M | ||
| Q1 25 | $28.7M | $12.7M | ||
| Q4 24 | $130.5M | $18.1M | ||
| Q3 24 | $34.6M | $5.3M | ||
| Q2 24 | $29.7M | $10.7M |
自由现金流GTYMLAB
| Q1 26 | — | — | ||
| Q4 25 | $127.0M | $18.0M | ||
| Q3 25 | $30.4M | $7.1M | ||
| Q2 25 | $34.6M | $884.0K | ||
| Q1 25 | $28.6M | $11.9M | ||
| Q4 24 | $129.6M | $17.3M | ||
| Q3 24 | $34.4M | $3.5M | ||
| Q2 24 | $29.6M | $9.9M |
自由现金流率GTYMLAB
| Q1 26 | — | — | ||
| Q4 25 | 209.8% | 27.7% | ||
| Q3 25 | 54.7% | 11.7% | ||
| Q2 25 | 64.9% | 1.5% | ||
| Q1 25 | 54.7% | 19.2% | ||
| Q4 24 | 244.5% | 27.6% | ||
| Q3 24 | 66.9% | 6.0% | ||
| Q2 24 | 59.2% | 16.9% |
资本支出强度GTYMLAB
| Q1 26 | — | — | ||
| Q4 25 | 0.7% | 1.1% | ||
| Q3 25 | 0.2% | 1.8% | ||
| Q2 25 | 0.3% | 1.7% | ||
| Q1 25 | 0.1% | 1.2% | ||
| Q4 24 | 1.7% | 1.3% | ||
| Q3 24 | 0.4% | 3.1% | ||
| Q2 24 | 0.3% | 1.5% |
现金转化率GTYMLAB
| Q1 26 | — | — | ||
| Q4 25 | 4.71× | 5.17× | ||
| Q3 25 | 1.31× | 3.32× | ||
| Q2 25 | 2.48× | 0.40× | ||
| Q1 25 | 1.94× | — | ||
| Q4 24 | 5.85× | — | ||
| Q3 24 | 2.26× | 1.54× | ||
| Q2 24 | 1.78× | 3.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GTY
暂无分部数据
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
